<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4986">
  <stage>Registered</stage>
  <submitdate>5/03/2015</submitdate>
  <approvaldate>5/03/2015</approvaldate>
  <nctid>NCT02385760</nctid>
  <trial_identification>
    <studytitle>CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris</studytitle>
    <scientifictitle>A Multi-centre, Double-blind, Randomized, Parallel Group, Placebo Controlled Efficacy and Safety Study of Oral CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CTX-4430-AV-201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acne Vulgaris</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - CTX-4430
Treatment: drugs - Placebo

Experimental: Active - CTX-4430 oral capsule, 100 mg, once-daily for 12 weeks

Placebo Comparator: Placebo - Placebo: identical oral capsule, without active ingredient, once-daily for 12 weeks


Treatment: drugs: CTX-4430


Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Efficacy as measured by inflammatory lesion counts - Change from baseline in inflammatory lesion count after 12 weeks of treatment as compared to placebo.</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety as measured by the incidence of treatment emergent adverse events - Incidence of treatment emergent adverse events as compared to placebo.</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy as measured by Investigator Global Assessment (IGA) - The proportion of participants achieving Grade 0 or 1 with a two grade improvement in the IGA from baseline to the end of the 12 weeks of treatment as compared to placebo.</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy as measured by non-inflammatory lesion counts - Change from baseline in non-inflammatory lesion counts after 12 weeks of treatment as compared to placebo.</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Must provide Informed consent.

          2. Male or female aged 16 to 44 inclusive.

          3. Moderate to severe facial acne vulgaris as defined in the protocol.</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>44</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Positive testing for HIV, HBsAg, or hepatitis C virus (HCV).

          2. Females who are pregnant, lactating, or planning to become pregnant during the study.

          3. Any systemic medical condition which, in the opinion of the investigator, would put
             the participant at risk by participation in the study.

          4. Any systemic or dermatologic disorder that, in the opinion of the investigator will
             interfere with the assessment of the study endpoints (e.g. psoriasis).

          5. Concurrent or previous use of an investigational drug or device within 30 days prior
             to screening.

          6. The presence of acne conglobata, acne fulminans, secondary acne, or nodulocystic acne.

          7. The presence of known or suspicious unresolved dermatological cancerous or
             pre-cancerous lesions.

          8. Hypersensitivity or idiosyncratic reaction to compounds related to CTX-4430 or any of
             its components.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>124</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Clinical Trials Woden Dermatology - Phillip</hospital>
    <hospital>St George Dermatology - Kogarah</hospital>
    <hospital>Central Sydney Dermatology - Sydney</hospital>
    <hospital>The Skin Centre - Benowa</hospital>
    <hospital>Siller Medical - Brisbane</hospital>
    <hospital>Veracity Clinical Research - Woolloongabba</hospital>
    <hospital>Skin and Cancer Foundation - Carlton</hospital>
    <hospital>Fremantle Dermatology - Fremantle</hospital>
    <postcode>2606 - Phillip</postcode>
    <postcode>2217 - Kogarah</postcode>
    <postcode>2000 - Sydney</postcode>
    <postcode>4217 - Benowa</postcode>
    <postcode>4000 - Brisbane</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3053 - Carlton</postcode>
    <postcode>6160 - Fremantle</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Celtaxsys, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Clinical Network Services (CNS) Pty Ltd</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Celtaxsys Aus Pty Limited</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A multi-centre, double-blind, randomized, parallel group, placebo controlled efficacy and
      safety study of oral CTX-4430 for the treatment of moderate to severe facial acne vulgaris.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02385760</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Lynda J Spelman, MB BS, FACD</name>
      <address>Veracity Clinical Research</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>